<p><strong>唐纳德·特朗普总统</strong> 在今年早些时候披露了价值高达 68 万美元的 <strong>礼来公司</strong> (NYSE: LLY) 的股票购买，这些交易发生在他任内的联邦机构推进有利于该制药商的 减肥药业务 之际。</p>
<h2>特朗普的礼来股票购买与 GLP-1 政策发展相吻合</h2>
<p>根据特朗普签署的披露表格，KFF 健康新闻 报道 截至 3 月底共进行了七笔礼来股票的购买。根据文件，第一次交易发生在 1 月 6 日。</p>
<p>这家公司在市场上的估值接近 1 万亿美元，已成为日益增长的 GLP-1 减肥药市场的重要参与者。</p>
<p>投资的时机与几项与医疗保险 覆盖肥胖治疗 相关的行政举措相吻合。</p>
<p>其中最显著的发展是医疗保险和医疗补助服务中心提出的一项试点计划，允许医疗保险患者以 每月约 50 美元 的费用获得 GLP-1 药物。</p>
<p>该提议被视为一项临时过渡计划，可能会导致未来对减肥治疗的医疗保险永久报销。制药商需在 1 月 8 日前提交参与申请。</p>
<p><strong>另请阅读：</strong>
<strong>最高法院驳回礼来在医疗补助欺诈案中的上诉</strong></p>
<p>礼来后来被列为该计划的参与制造商之一。该公司将其纳入视为其肥胖治疗业务的一个 “重要里程碑”。</p>
<h2>西氏医药投资也与 GLP-1 市场相关</h2>
<p>特朗普的披露还显示，他在 2 月 10 日购买了西氏医药服务的股票 (NYSE: WST)，价值在 25 万到 50 万美元之间。</p>
<p>西氏医药制造用于药物治疗的注射给药系统，最近提到其 GLP-1 部门的增长是 季度收入增长 的一个因素。</p>
<h2>特朗普组织表示投资由独立管理</h2>
<p>特朗普组织的一位发言人告诉路透社，特朗普的投资持有通过由第三方金融机构独立管理的自主账户进行维护。</p>
<p>根据声明，交易决策和投资组合平衡通过这些公司的自动化系统进行处理。</p>
<p>路透社报道称，总统的资产由其子女控制的信托持有。</p>
<p><strong>LLY 价格动态：</strong> 截至周二发布时，礼来股票上涨 2.73%，报 1015.09 美元，根据 Benzinga Pro 数据。</p>
<p>在过去一个月中，LLY 上涨约 9.4%，而标准普尔 500 指数上涨 3.9%，年初至今下跌约 6%，相比之下该指数上涨 7.4%。</p>
<p><em>图片来源于 Shutterstock</em></p>
<p><strong>另请阅读：</strong>
<strong>前特斯拉 AI 总监加入 Anthropic：安德烈·卡帕西如何转变阵营</strong></p>

礼来

西氏医药服务

2 倍做多 LLY ETF - Direxion

美国制药 ETF - iShares

2 倍做多 LLY ETF - Defiance

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

<p>唐纳德·特朗普披露了在礼来公司购买股票的金额高达 68 万美元，因为医疗保险计划推进了 GLP-1 药物的覆盖。这些投资与有利于该制药公司肥胖症治疗的政策相吻合。特朗普的购买还包括西氏医药服务的股票，价值在 25 万到 50 万美元之间。一位发言人表示，他的投资由第三方机构独立管理。礼来公司的股票上涨了 2.73%，达到 1015.09 美元，过去一个月上涨了 9.4%</p>

<p><strong>President Donald Trump</strong> disclosed stock purchases worth as much as $680,000 in <strong>Eli Lilly &amp; Co.</strong> (NYSE: LLY) earlier this year, with the trades occurring as federal agencies under his administration advanced policies that benefited the drugmaker's obesity drug business.</p>
<div class="lb-trans"><p><strong>唐纳德·特朗普总统</strong> 在今年早些时候披露了价值高达 68 万美元的 <strong>礼来公司</strong> (NYSE: LLY) 的股票购买，这些交易发生在他任内的联邦机构推进有利于该制药商的 减肥药业务 之际。</p>
</div><h2>Trump's Eli Lilly Purchases Coincided With GLP-1 Policy Developments</h2>
<div class="lb-trans"><h2>特朗普的礼来股票购买与 GLP-1 政策发展相吻合</h2>
</div><p>Citing disclosure forms signed by Trump, KFF Health News reported seven purchases of Eli Lilly shares through the end of March. The first transaction occurred on January 6, according to the filings.</p>
<div class="lb-trans"><p>根据特朗普签署的披露表格，KFF 健康新闻 报道 截至 3 月底共进行了七笔礼来股票的购买。根据文件，第一次交易发生在 1 月 6 日。</p>
</div><p>The company, valued at nearly $1 trillion by the market, has become a major player in the growing GLP-1 weight-loss drug market.</p>
<div class="lb-trans"><p>这家公司在市场上的估值接近 1 万亿美元，已成为日益增长的 GLP-1 减肥药市场的重要参与者。</p>
</div><p>The timing of the investments aligned with several administration initiatives tied to Medicare coverage of obesity treatments.</p>
<div class="lb-trans"><p>投资的时机与几项与医疗保险 覆盖肥胖治疗 相关的行政举措相吻合。</p>
</div><p>Among the most notable developments was a proposal from the Centers for Medicare &amp; Medicaid Services for a pilot program that would allow Medicare patients to access GLP-1 drugs for about $50 per month.</p>
<div class="lb-trans"><p>其中最显著的发展是医疗保险和医疗补助服务中心提出的一项试点计划，允许医疗保险患者以 每月约 50 美元 的费用获得 GLP-1 药物。</p>
</div><p>The proposed initiative was viewed as a temporary bridge program that could later lead to permanent Medicare reimbursement for weight-loss treatments. Drugmakers were required to submit applications for participation by January 8.</p>
<div class="lb-trans"><p>该提议被视为一项临时过渡计划，可能会导致未来对减肥治疗的医疗保险永久报销。制药商需在 1 月 8 日前提交参与申请。</p>
</div><p><strong>Read Also:</strong>
<strong>Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case</strong></p>
<div class="lb-trans"><p><strong>另请阅读：</strong>
<strong>最高法院驳回礼来在医疗补助欺诈案中的上诉</strong></p>
</div><p>Eli Lilly was later named as one of the participating manufacturers in the program. The company described the inclusion as a &#34;significant milestone&#34; for its obesity treatment business.</p>
<div class="lb-trans"><p>礼来后来被列为该计划的参与制造商之一。该公司将其纳入视为其肥胖治疗业务的一个 “重要里程碑”。</p>
</div><h2>West Pharmaceutical Investment Also Tied To GLP-1 Market</h2>
<div class="lb-trans"><h2>西氏医药投资也与 GLP-1 市场相关</h2>
</div><p>Trump's disclosures also revealed a February 10 purchase of shares in West Pharmaceutical Services (NYSE: WST), valued between $250,000 and $500,000.</p>
<div class="lb-trans"><p>特朗普的披露还显示，他在 2 月 10 日购买了西氏医药服务的股票 (NYSE: WST)，价值在 25 万到 50 万美元之间。</p>
</div><p>West Pharmaceutical manufactures injectable delivery systems used in drug treatments and recently cited growth in its GLP-1 segment as a contributor to higher quarterly revenue.</p>
<div class="lb-trans"><p>西氏医药制造用于药物治疗的注射给药系统，最近提到其 GLP-1 部门的增长是 季度收入增长 的一个因素。</p>
</div><h2>Trump Organization Says Investments Are Independently Managed</h2>
<div class="lb-trans"><h2>特朗普组织表示投资由独立管理</h2>
</div><p>A spokesperson for the Trump Organization told Reuters that Trump's investment holdings are maintained through discretionary accounts managed independently by third-party financial institutions.</p>
<div class="lb-trans"><p>特朗普组织的一位发言人告诉路透社，特朗普的投资持有通过由第三方金融机构独立管理的自主账户进行维护。</p>
</div><p>According to the statement, trading decisions and portfolio balancing are handled through automated systems controlled by those firms.</p>
<div class="lb-trans"><p>根据声明，交易决策和投资组合平衡通过这些公司的自动化系统进行处理。</p>
</div><p>According to Reuters, the ​president's assets are held in a trust controlled by his children.</p>
<div class="lb-trans"><p>路透社报道称，总统的资产由其子女控制的信托持有。</p>
</div><p><strong>LLY Price Action:</strong> Eli Lilly shares were up 2.73% at $1015.09 at the time of publication on Tuesday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>LLY 价格动态：</strong> 截至周二发布时，礼来股票上涨 2.73%，报 1015.09 美元，根据 Benzinga Pro 数据。</p>
</div><p>Over the past month, LLY has gained about 9.4% versus a 3.9% rise in the S&amp;P 500 and is down roughly 6% year-to-date compared to the index's 7.4% gain.</p>
<div class="lb-trans"><p>在过去一个月中，LLY 上涨约 9.4%，而标准普尔 500 指数上涨 3.9%，年初至今下跌约 6%，相比之下该指数上涨 7.4%。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div><p><strong>Read Also:</strong>
<strong>Ex-Tesla AI Director Joins Anthropic: How Andrej Karpathy Switched Sides</strong></p>
<div class="lb-trans"><p><strong>另请阅读：</strong>
<strong>前特斯拉 AI 总监加入 Anthropic：安德烈·卡帕西如何转变阵营</strong></p>
</div>

报告称，特朗普的股票选择与新的医疗保险规则完美契合